

jerome Honnorat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4655992/publications.pdf>

Version: 2024-02-01

278
papers

19,691
citations

13865

67
h-index

14759

127
g-index

294
all docs

294
docs citations

294
times ranked

16269
citing authors

#	ARTICLE	IF	CITATIONS
1	A clinical approach to diagnosis of autoimmune encephalitis. <i>Lancet Neurology</i> , The, 2016, 15, 391-404.	10.2	2,782
2	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2535.	7.4	982
3	Radiotherapy for Glioblastoma in the Elderly. <i>New England Journal of Medicine</i> , 2007, 356, 1527-1535.	27.0	736
4	NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality. <i>European Journal of Cancer</i> , 2012, 48, 2192-2202.	2.8	661
5	Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3 β phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease. <i>Genes To Cells</i> , 2005, 10, 165-179.	1.2	377
6	Cerebellar Ataxia With Anti-glutamic Acid Decarboxylase Antibodies. <i>Archives of Neurology</i> , 2001, 58, 225.	4.5	371
7	Paraneoplastic Neurologic Syndrome in the PNS Euronetwork Database. <i>Archives of Neurology</i> , 2010, 67, 330.	4.5	315
8	Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	313
9	Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. <i>Brain</i> , 2012, 135, 1606-1621.	7.6	272
10	The pattern and diagnostic criteria of sensory neuropathy: a case-control study. <i>Brain</i> , 2009, 132, 1723-1733.	7.6	259
11	Paraneoplastic neurological syndromes. <i>Orphanet Journal of Rare Diseases</i> , 2007, 2, 22.	2.7	252
12	Collapsin Response Mediator Proteins (CRMPs): Involvement in Nervous System Development and Adult Neurodegenerative Disorders. <i>Molecular Neurobiology</i> , 2003, 28, 51-64.	4.0	244
13	Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. <i>Brain</i> , 2002, 125, 166-175.	7.6	240
14	Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. <i>Annals of Neurology</i> , 2007, 61, 544-551.	5.3	218
15	Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 80, 412-416.	1.9	217
16	Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. <i>Neurology</i> , 2014, 82, 556-563.	1.1	202
17	Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: Data from the French-Italian HHT network. <i>Genetics in Medicine</i> , 2007, 9, 14-22.	2.4	196
18	Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3050-3055.	1.6	196

#	ARTICLE	IF	CITATIONS
19	Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. <i>Brain</i> , 2010, 133, 2578-2591.	7.6	180
20	Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylase, methylase, methylase, methylase) Tj ETQq0 0 0 rgBT /Overlock 10 1 O6-methylguanine-DNA-methyltransferase in a series of 100 glioblastoma patients. <i>Cancer</i> , 2012, 118, 4201-4211.	4.1	172
21	Factors Influencing Early Admission in a French Stroke Unit. <i>Stroke</i> , 2002, 33, 153-159.	2.0	170
22	Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. <i>Annals of Neurology</i> , 2001, 49, 214-221.	5.3	167
23	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter. <i>Neuro-Oncology</i> , 2022, 24, 1935-1949.	1.2	165
24	Aquaporin-4 antibody-negative neuromyelitis optica. <i>Neurology</i> , 2013, 80, 2194-2200.	1.1	157
25	Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. <i>Brain</i> , 2016, 139, 1079-1093.	7.6	157
26	Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures. <i>JAMA Neurology</i> , 2016, 73, 1115.	9.0	155
27	Antiampiphysin Antibodies Are Associated With Various Paraneoplastic Neurological Syndromes and Tumors. <i>Archives of Neurology</i> , 1999, 56, 172.	4.5	152
28	Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. <i>Neuro-Oncology</i> , 2010, 12, 725-735.	1.2	149
29	Guidelines for treatment of immune-mediated cerebellar ataxias. <i>Cerebellum and Ataxias</i> , 2015, 2, 14.	1.9	143
30	Consensus Paper: Neuroimmune Mechanisms of Cerebellar Ataxias. <i>Cerebellum</i> , 2016, 15, 213-232.	2.5	142
31	Neuroleptic intolerance in patients with anti-NMDAR encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e280.	6.0	139
32	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2018, 4, 495.	7.1	135
33	Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	129
34	Isolation and Expression Pattern of Human Unc-33-Like Phosphoprotein 6/Collapsin Response Mediator Protein 5 (Ulip6/CRMP5): Coexistence with Ulip2/CRMP2 in Sema3A- Sensitive Oligodendrocytes. <i>Journal of Neuroscience</i> , 2001, 21, 7203-7214.	3.6	126
35	Clinical Spectrum of Encephalitis Associated With Antibodies Against the Î±-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor. <i>JAMA Neurology</i> , 2015, 72, 1163.	9.0	123
36	Thrombolysis for Ischemic Stroke in Patients with Old Microbleeds on Pretreatment MRI. <i>Cerebrovascular Diseases</i> , 2004, 17, 238-241.	1.7	113

#	ARTICLE	IF	CITATIONS
37	Neurologic Adverse Events of Immune Checkpoint Inhibitors. <i>Neurology</i> , 2021, 96, 754-766.	1.1	109
38	NMO-IgG and Devic's neuromyelitis optica: a French experience. <i>Multiple Sclerosis Journal</i> , 2008, 14, 440-445.	3.0	107
39	Regulation of Spine Development by Semaphorin3A through Cyclin-Dependent Kinase 5 Phosphorylation of Collapsin Response Mediator Protein 1. <i>Journal of Neuroscience</i> , 2007, 27, 12546-12554.	3.6	105
40	Treatment and outcome of children and adolescents with N-methyl-d-aspartate receptor encephalitis. <i>Journal of Neurology</i> , 2015, 262, 1859-1866.	3.6	105
41	French brain tumor data bank: Methodology and first results on 10,000 cases. <i>Journal of Neuro-Oncology</i> , 2007, 84, 189-199.	2.9	103
42	A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy. <i>Clinical Cancer Research</i> , 2012, 18, 5071-5080.	7.0	103
43	Anti-N-Methyl-Aspartate Receptor Encephalitis in Adult Patients Requiring Intensive Care. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 491-499.	5.6	103
44	Epidemiology of paraneoplastic neurological syndromes: a population-based study. <i>Journal of Neurology</i> , 2020, 267, 26-35.	3.6	103
45	In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. <i>Orphanet Journal of Rare Diseases</i> , 2010, 5, 31.	2.7	102
46	Surface dynamics of GluN2B-NMDA receptors controls plasticity of maturing glutamate synapses. <i>EMBO Journal</i> , 2014, 33, 842-861.	7.8	101
47	Early Fibrinogen Degradation Coagulopathy Is Predictive of Parenchymal Hematomas in Cerebral rt-PA Thrombolysis. <i>Stroke</i> , 2004, 35, 1323-1328.	2.0	99
48	Metabotropic Glutamate Receptor Type 1 Autoantibody-Associated Cerebellitis. <i>Archives of Neurology</i> , 2010, 67, 627-30.	4.5	99
49	MRI Monitoring of Neuroinflammation in Mouse Focal Ischemia. <i>Stroke</i> , 2007, 38, 131-137.	2.0	94
50	Central nervous system complications associated with immune checkpoint inhibitors. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 772-778.	1.9	92
51	Phosphorylation of CRMP2 (Collapsin Response Mediator Protein 2) Is Involved in Proper Dendritic Field Organization. <i>Journal of Neuroscience</i> , 2012, 32, 1360-1365.	3.6	88
52	New targeted therapies in pituitary carcinoma resistant to temozolomide. <i>Pituitary</i> , 2012, 15, 37-43.	2.9	87
53	A New Mutation of the <i>IL13</i> Gene, G303V, in Early-Onset Familial Progressive Supranuclear Palsy. <i>Archives of Neurology</i> , 2005, 62, 1444.	4.5	86
54	Collapsin Response Mediator Protein 1 Mediates Reelin Signaling in Cortical Neuronal Migration. <i>Journal of Neuroscience</i> , 2006, 26, 13357-13362.	3.6	82

#	ARTICLE	IF	CITATIONS
55	Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. <i>Neuro-Oncology</i> , 2010, 12, 1078-1082.	1.2	81
56	Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience. <i>Journal of Neurology</i> , 2011, 258, 2058-2068.	3.6	81
57	Paraneoplastic Cerebellar Syndrome and Optic Neuritis With Anti-CV2 Antibodies. <i>Archives of Neurology</i> , 1998, 55, 405.	4.5	75
58	Matrix-Binding Vascular Endothelial Growth Factor (VEGF) Isoforms Guide Granule Cell Migration in the Cerebellum via VEGF Receptor Flk1. <i>Journal of Neuroscience</i> , 2010, 30, 15052-15066.	3.6	75
59	Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 3.	2.7	75
60	Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. , 2019, 7, 337.		75
61	Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	74
62	Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	74
63	Calpain product of WT-CRMP2 reduces the amount of surface NR2B NMDA receptor subunit. <i>Journal of Neurochemistry</i> , 2006, 98, 1252-1265.	3.9	73
64	Cerebrospinal Fluid Dendritic Cells Infiltrate the Brain Parenchyma and Target the Cervical Lymph Nodes under Neuroinflammatory Conditions. <i>PLoS ONE</i> , 2008, 3, e3321.	2.5	73
65	Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. <i>Acta Neuropathologica</i> , 2018, 135, 569-579.	7.7	73
66	Involvement of collapsin response mediator proteins in the neurite extension induced by neurotrophins in dorsal root ganglion neurons. <i>Molecular and Cellular Neurosciences</i> , 2004, 25, 433-443.	2.2	69
67	Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. <i>Journal of Neuro-Oncology</i> , 2010, 97, 73-80.	2.9	69
68	Early electro-clinical features may contribute to diagnosis of the anti-NMDA receptor encephalitis in children. <i>Clinical Neurophysiology</i> , 2013, 124, 2354-2361.	1.5	69
69	Expanding Spectrum of Encephalitis With NMDA Receptor Antibodies in Young Children. <i>Journal of Child Neurology</i> , 2010, 25, 742-745.	1.4	68
70	Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. <i>Neurology</i> , 2013, 80, 2226-2232.	1.1	68
71	Cell- and Single Molecule-Based Methods to Detect Anti- N -Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project. <i>Biological Psychiatry</i> , 2017, 82, 766-772.	1.3	67
72	Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes. <i>European Journal of Neuroscience</i> , 1999, 11, 4226-4232.	2.6	65

#	ARTICLE	IF	CITATIONS
73	Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e371.	6.0	64
74	Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies. <i>Journal of Neurology</i> , 2018, 265, 2190-2200.	3.6	64
75	Early-Stage Investigations of Ultrasmall Superparamagnetic Iron Oxide-Induced Signal Change After Permanent Middle Cerebral Artery Occlusion in Mice. <i>Stroke</i> , 2009, 40, 1834-1841.	2.0	63
76	Associations between HLA and autoimmune neurological diseases with autoantibodies. <i>Autoimmunity Highlights</i> , 2020, 11, 2.	3.9	63
77	CRMP3 is required for hippocampal CA1 dendritic organization and plasticity. <i>FASEB Journal</i> , 2008, 22, 401-409.	0.5	62
78	CRMP5 Interacts with Tubulin to Inhibit Neurite Outgrowth, Thereby Modulating the Function of CRMP2. <i>Journal of Neuroscience</i> , 2010, 30, 10639-10654.	3.6	62
79	Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 38.	5.2	62
80	Hypointense Transcerebral Veins at T2*-Weighted MRI: A Marker of Hemorrhagic Transformation Risk in Patients Treated with Intravenous Tissue Plasminogen Activator. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, 23, 1362-1370.	4.3	60
81	Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. <i>Neurology</i> , 2020, 95, e3012-e3025.	1.1	60
82	Diagnostic Criteria for Primary Autoimmune Cerebellar Ataxia—Guidelines from an International Task Force on Immune-Mediated Cerebellar Ataxias. <i>Cerebellum</i> , 2020, 19, 605-610.	2.5	60
83	Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. <i>Neuro-Oncology</i> , 2014, 16, 662-670.	1.2	59
84	Disease-specific monoclonal antibodies targeting glutamate decarboxylase impair GABAergic neurotransmission and affect motor learning and behavioral functions. <i>Frontiers in Behavioral Neuroscience</i> , 2015, 9, 78.	2.0	59
85	Isolated seizures are a common early feature of paraneoplastic anti-GABAB receptor encephalitis. <i>Journal of Neurology</i> , 2019, 266, 195-206.	3.6	58
86	Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	58
87	Seizure specificities in patients with antibody-mediated autoimmune encephalitis. <i>Epilepsia</i> , 2019, 60, 1508-1525.	5.1	57
88	Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093279.	3.5	57
89	Contactin-associated protein-like 2, a protein of the neurexin family involved in several human diseases. <i>European Journal of Neuroscience</i> , 2018, 48, 1906-1923.	2.6	56
90	Inhibitory axons are targeted in hippocampal cell culture by anti-Caspr2 autoantibodies associated with limbic encephalitis. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 265.	3.7	54

#	ARTICLE	IF	CITATIONS
91	Collapsin Response Mediator Protein 4a (CRMP4a) Is Upregulated in Motoneurons of Mutant SOD1 Mice and Can Trigger Motoneuron Axonal Degeneration and Cell Death. <i>Journal of Neuroscience</i> , 2010, 30, 785-796.	3.6	53
92	Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1076-1084.	1.9	53
93	CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. <i>Neuro-Oncology</i> , 2015, 17, 1497-1503.	1.2	52
94	Autoimmune encephalitis in psychiatric institutions: current perspectives. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2775-2787.	2.2	52
95	Microarray gene expression profiling in meningiomas: Differential expression according to grade or histopathological subtype. <i>International Journal of Oncology</i> , 2009, 35, 1395-407.	3.3	51
96	IQGAP1 Protein Specifies Amplifying Cancer Cells in Glioblastoma Multiforme. <i>Cancer Research</i> , 2006, 66, 9074-9082.	0.9	50
97	Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies. <i>Neurology</i> , 2017, 88, 514-524.	1.1	49
98	Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1347-1355.	1.9	48
99	Intrathecal treatment of anti-Methylaspartate receptor encephalitis in children. <i>Developmental Medicine and Child Neurology</i> , 2015, 57, 95-99.	2.1	48
100	Phosphorylation of Collapsin Response Mediator Protein 2 on Tyr-479 Regulates CXCL12-induced T Lymphocyte Migration. <i>Journal of Biological Chemistry</i> , 2009, 284, 13265-13276.	3.4	47
101	Up-front temozolomide in elderly patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2010, 99, 89-94.	2.9	47
102	Processing and Nuclear Localization of CRMP2 during Brain Development Induce Neurite Outgrowth Inhibition. <i>Journal of Biological Chemistry</i> , 2008, 283, 14751-14761.	3.4	46
103	Monoclonal antibodies to 65kDa glutamate decarboxylase induce epitope specific effects on motor and cognitive functions in rats. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 82.	2.7	46
104	Seronegative paraneoplastic cerebellar degeneration: the PNS Euronetwork experience. <i>European Journal of Neurology</i> , 2014, 21, 731-735.	3.3	46
105	Pp IX Silica Nanoparticles Demonstrate Differential Interactions with <i>In Vitro</i> Tumor Cell Lines and <i>In Vivo</i> Mouse Models of Human Cancers. <i>Photochemistry and Photobiology</i> , 2010, 86, 213-222.	2.5	44
106	TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration. <i>Cerebellum</i> , 2019, 18, 245-254.	2.5	44
107	Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. <i>Neurology</i> , 2021, 96, e866-e875.	1.1	44
108	Ethical Issues of Informed Consent in Acute Stroke. <i>Cerebrovascular Diseases</i> , 2005, 19, 65-68.	1.7	43

#	ARTICLE	IF	CITATIONS
109	Transient alterations in granule cell proliferation, apoptosis and migration in postnatal developing cerebellum of CRMP1 ^{-/-} mice. <i>Genes To Cells</i> , 2006, 11, 1337-1352.	1.2	43
110	Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine. <i>Clinical Drug Investigation</i> , 2016, 36, 783-789.	2.2	43
111	Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	43
112	In Vitro and In Vivo Models of Cerebral Ischemia Show Discrepancy in Therapeutic Effects of M2 Macrophages. <i>PLoS ONE</i> , 2013, 8, e67063.	2.5	43
113	Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 325-327.	1.9	41
114	VEGF modulates NMDA receptors activity in cerebellar granule cells through Src-family kinases before synapse formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13782-13787.	7.1	41
115	Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 789-792.	1.9	41
116	Anti-CV2 Autoantibodies and Paraneoplastic Neurological Syndromes. <i>Clinical Reviews in Allergy and Immunology</i> , 2000, 19, 51-60.	6.5	40
117	Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. <i>Lung Cancer</i> , 2006, 53, 51-58.	2.0	40
118	Anti-GAD Antibodies and Periodic Alternating Nystagmus. <i>Archives of Neurology</i> , 2005, 62, 1300.	4.5	39
119	Redifferentiation therapy in brain tumors: long-lasting complete regression of glioblastomas and anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol. <i>Journal of Neuro-Oncology</i> , 2001, 51, 57-66.	2.9	38
120	Expression of collapsin response mediator proteins 1, 2 and 5 is differentially regulated in newly generated and mature neurons of the adult olfactory system. <i>European Journal of Neuroscience</i> , 2005, 21, 2635-2648.	2.6	38
121	Peri-ictal pseudoprogression in patients with brain tumor. <i>Neuro-Oncology</i> , 2011, 13, 775-782.	1.2	38
122	Immune-mediated ataxias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 155, 313-332.	1.8	38
123	Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. <i>Practical Neurology</i> , 2022, 22, 19-31.	1.1	38
124	An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. <i>Molecular Cancer</i> , 2010, 9, 234.	19.2	37
125	Advances in paraneoplastic neurological syndromes. <i>Current Opinion in Oncology</i> , 2004, 16, 614-620.	2.4	36
126	Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. <i>Journal of Neurology</i> , 2011, 258, 27-33.	3.6	36

#	ARTICLE	IF	CITATIONS
127	Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson's disease. <i>Glia</i> , 2013, 61, 1645-1658.	4.9	35
128	CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling. <i>Cancer Research</i> , 2015, 75, 3519-3528.	0.9	35
129	POP66, A Paraneoplastic Encephalomyelitis-related Antigen, Is a Marker of Adult Oligodendrocytes. <i>Journal of Neuropathology and Experimental Neurology</i> , 1998, 57, 311-322.	1.7	34
130	Potential Role of Anti-GAD Antibodies in Abnormal Eye Movements. <i>Annals of the New York Academy of Sciences</i> , 2005, 1039, 446-454.	3.8	34
131	Drug Binding Assays do not Reveal Specific Binding of Lacosamide to Collapsin Response Mediator Protein 2 (CRMP2). <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 493-500.	3.9	33
132	Pseudotumoral presentation of cerebral amyloid angiopathy-related inflammation. <i>Neurology</i> , 2016, 86, 912-919.	1.1	33
133	ATAD3B is a human embryonic stem cell specific mitochondrial protein, re-expressed in cancer cells, that functions as dominant negative for the ubiquitous ATAD3A. <i>Mitochondrion</i> , 2012, 12, 441-448.	3.4	32
134	Anti-NMDA-R encephalitis: Should we consider extreme delta brush as electrical status epilepticus?. <i>Neurophysiologie Clinique</i> , 2016, 46, 17-25.	2.2	32
135	Beware of optic neuritis!. <i>Lancet Neurology</i> , The, 2002, 1, 516-517.	10.2	31
136	Extensive Expression of Collapsin Response Mediator Protein 5 (CRMP5) is a Specific Marker of High-grade Lung Neuroendocrine Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1699-1708.	3.7	31
137	Delayed onset of a second paraneoplastic neurological syndrome in eight patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 937-939.	1.9	31
138	Telomere Profiling: Toward Glioblastoma Personalized Medicine. <i>Molecular Neurobiology</i> , 2013, 47, 64-76.	4.0	31
139	Paraneoplastic disorders of the central and peripheral nervous systems. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 121, 1159-1179.	1.8	31
140	Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome. <i>Journal of Neurology</i> , 2019, 266, 398-410.	3.6	31
141	Update on paraneoplastic neurological syndromes. <i>Current Opinion in Oncology</i> , 2009, 21, 566-572.	2.4	30
142	Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). <i>Oncologist</i> , 2018, 23, 524.	3.7	30
143	Glioblastoma as differential diagnosis of autoimmune encephalitis. <i>Journal of Neurology</i> , 2018, 265, 669-677.	3.6	30
144	Characteristics of gliomas in patients with somatic IDH mosaicism. <i>Acta Neuropathologica Communications</i> , 2016, 4, 31.	5.2	29

#	ARTICLE	IF	CITATIONS
145	CRMP5 Regulates Generation and Survival of Newborn Neurons in Olfactory and Hippocampal Neurogenic Areas of the Adult Mouse Brain. PLoS ONE, 2011, 6, e23721.	2.5	29
146	Effects of diabetes type and treatment on zinc status in diabetes mellitus. Biological Trace Element Research, 1992, 32, 311-316.	3.5	28
147	Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis. Journal of Neurology, 2011, 258, 328-329.	3.6	28
148	Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome. Neurology, 2015, 85, 2076-2078.	1.1	28
149	Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. Neurology, 2017, 88, 1235-1242.	1.1	28
150	Methionine tumor starvation by erythrocyte-encapsulated methionine gamma-lyase activity controlled with per os vitamin B6. Cancer Medicine, 2017, 6, 1437-1452.	2.8	28
151	Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. Journal of Neurology, 2020, 267, 2083-2089.	3.6	28
152	Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. Brain Communications, 2021, 3, fcab185.	3.3	28
153	Collapsin response mediator protein-3/unc-33-like protein-4 gene: organization, chromosomal mapping and expression in the developing mouse brain. Gene, 2000, 242, 175-182.	2.2	27
154	NG2-expressing glial precursor cells are a new potential oligodendroglioma cell initiating population in N-ethyl-N-nitrosourea-induced gliomagenesis. Carcinogenesis, 2010, 31, 1718-1725.	2.8	27
155	Paraneoplastic antibodies detected by isoelectric focusing of cerebrospinal fluid and serum. Journal of Neuroimmunology, 2004, 155, 150-154.	2.3	26
156	Initial clinical presentation of young children with N-methyl-D-aspartate receptor encephalitis. European Journal of Paediatric Neurology, 2018, 22, 404-411.	1.6	26
157	Encephalitis with Autoantibodies against the Glutamate Kainate Receptors <sc>GluK2</sc>. Annals of Neurology, 2021, 90, 101-117.	5.3	26
158	Missense variants in DPYSL5 cause a neurodevelopmental disorder with corpus callosum agenesis and cerebellar abnormalities. American Journal of Human Genetics, 2021, 108, 951-961.	6.2	26
159	SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas. PLoS ONE, 2012, 7, e45950.	2.5	25
160	Potential side effect of propofol and sevoflurane for anesthesia of anti-NMDA-R encephalitis. BMC Anesthesiology, 2014, 14, 5.	1.8	25
161	Autoimmune channelopathies in paraneoplastic neurological syndromes. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2665-2676.	2.6	25
162	Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma. Molecular Cancer, 2015, 14, 134.	19.2	25

#	ARTICLE	IF	CITATIONS
163	Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e68.	6.0	25
164	Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 347-358.	1.9	24
165	Are the 'newly discovered' paraneoplastic anti-collapsin response-mediator protein 5 antibodies simply anti-cv2 antibodies?. <i>Annals of Neurology</i> , 2001, 50, 688-690.	5.3	23
166	HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. <i>Journal of Neuroimmunology</i> , 2010, 226, 147-149.	2.3	23
167	Clinical presentation of immune-mediated cerebellar ataxia. <i>Revue Neurologique</i> , 2011, 167, 408-417.	1.5	23
168	Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis. <i>Neuro-Oncology</i> , 2014, 16, 1484-1498.	1.2	23
169	Nonparaneoplastic autoimmune cerebellar ataxias. <i>Current Opinion in Neurology</i> , 2019, 32, 484-492.	3.6	23
170	Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. <i>Brain</i> , 2021, 144, 2709-2721.	7.6	23
171	Molecular cloning of a new unc-33-like cDNA from rat brain and its relation to paraneoplastic neurological syndromes. <i>Molecular Brain Research</i> , 1997, 46, 329-332.	2.3	22
172	Paraneoplastic Neurological Syndromes: General Treatment Overview. <i>Current Treatment Options in Neurology</i> , 2013, 15, 150-168.	1.8	22
173	Expression of the onconeural CV2/CRMP5 antigen in thymus and thymoma. <i>Journal of Neuroimmunology</i> , 2006, 174, 168-173.	2.3	21
174	Mapping CRMP3 domains involved in dendrite morphogenesis and voltage-gated calcium channel regulation. <i>Journal of Cell Science</i> , 2013, 126, 4262-73.	2.0	21
175	Extensive myelitis associated with anti-NMDA receptor antibodies. <i>BMC Neurology</i> , 2013, 13, 211.	1.8	21
176	Neuronal central nervous system syndromes probably mediated by autoantibodies. <i>European Journal of Neuroscience</i> , 2016, 43, 1535-1552.	2.6	21
177	Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4. <i>Oncotarget</i> , 2017, 8, 23750-23759.	1.8	21
178	Mild Encephalitis/Encephalopathy with reversible splenial lesion syndrome: An unusual presentation of anti-GFAP astrocytopathy. <i>European Journal of Paediatric Neurology</i> , 2020, 26, 89-91.	1.6	21
179	USPIO-Enhanced MRI of Neuroinflammation at the Sub-Acute Stage of Ischemic Stroke: Preliminary Data. <i>Cerebrovascular Diseases</i> , 2007, 24, 544-546.	1.7	20
180	New concepts in paraneoplastic neurological syndromes. <i>Revue Neurologique</i> , 2011, 167, 729-736.	1.5	20

#	ARTICLE	IF	CITATIONS
181	The Collapsin Response Mediator Protein 5 Onconeural Protein Is Expressed in Schwann Cells Under Axonal Signals and Regulates Axon-Schwann Cell Interactions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 298-311.	1.7	20
182	Immunoglobulin G antibodies to the N-Methyl-D-Aspartate receptor are distinct from immunoglobulin A and immunoglobulin M responses. <i>Annals of Neurology</i> , 2015, 77, 183-183.	5.3	20
183	Stroke-Like Presentation of Paraneoplastic Cerebellar Degeneration: a Single-Center Experience and Review of the Literature. <i>Cerebellum</i> , 2019, 18, 976-982.	2.5	20
184	Impact of anti-CASPR2 autoantibodies from patients with autoimmune encephalitis on CASPR2/TAG-1 interaction and Kv1 expression. <i>Journal of Autoimmunity</i> , 2019, 103, 102284.	6.5	20
185	Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13127.	4.1	20
186	Full recovery of agrypnia associated with anti-Lgi1 antibodies encephalitis under immunomodulatory treatment: A case report with sequential polysomnographic assessment. <i>Sleep Medicine</i> , 2012, 13, 554-556.	1.6	19
187	Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients. <i>Hematological Oncology</i> , 2013, 31, 57-64.	1.7	19
188	Collapsin response mediator protein 5 (CRMP5) phosphorylation at threonine 516 regulates neurite outgrowth inhibition. <i>European Journal of Neuroscience</i> , 2014, 40, 3010-3020.	2.6	19
189	Autoimmune N-methyl-D-aspartate receptor encephalitis is a differential diagnosis of infectious encephalitis. <i>Journal of Infection</i> , 2014, 68, 419-425.	3.3	19
190	Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1261-1270.	4.1	19
191	Fundamental Mechanisms of Autoantibody-Induced Impairments on Ion Channels and Synapses in Immune-Mediated Cerebellar Ataxias. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4936.	4.1	19
192	CSF IgA NMDAR antibodies are potential biomarkers for teratomas in anti-NMDAR encephalitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e166.	6.0	18
193	Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment. <i>Journal of Neurology</i> , 2020, 267, 2154-2156.	3.6	18
194	Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies. <i>Journal of Neurology</i> , 2020, 267, 1906-1911.	3.6	18
195	Onconeural antibodies are essential to diagnose paraneoplastic neurological syndromes. <i>Acta Neurologica Scandinavica</i> , 2006, 113, 64-68.	2.1	17
196	Collapsin Response Mediator Protein 5 (CRMP5) Induces Mitophagy, Thereby Regulating Mitochondrion Numbers in Dendrites. <i>Journal of Biological Chemistry</i> , 2014, 289, 2261-2276.	3.4	17
197	Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies. <i>Journal of Neuroimmunology</i> , 2018, 315, 28-32.	2.3	17
198	Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses. <i>Cerebellum</i> , 2022, 21, 573-591.	2.5	17

#	ARTICLE	IF	CITATIONS
199	Multiplex family with GAD65-Abs neurologic syndromes. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e416.	6.0	16
200	Transcriptional regulation of CRMP5 controls neurite outgrowth through Sox5. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 67-79.	5.4	16
201	Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2000-2000.	1.6	16
202	Myorhythmia associated with Hodgkin's lymphoma. <i>Journal of Neurology</i> , 2003, 250, 1382-1384.	3.6	15
203	Paraneoplastic subacute lower motor neuron syndrome associated with solid cancer. <i>Journal of the Neurological Sciences</i> , 2015, 358, 413-416.	0.6	15
204	Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies. <i>British Journal of Cancer</i> , 2018, 119, 105-113.	6.4	15
205	Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	15
206	Role of LGI1 protein in synaptic transmission: From physiology to pathology. <i>Neurobiology of Disease</i> , 2021, 160, 105537.	4.4	15
207	G303V tau mutation presenting with progressive supranuclear palsy—like features. <i>Movement Disorders</i> , 2012, 27, 581-583.	3.9	14
208	Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders. <i>Frontiers in Genetics</i> , 2013, 4, 181.	2.3	14
209	Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis. <i>Biological Psychiatry</i> , 2021, 90, 9-15.	1.3	14
210	Cerebrospinal Fluid IL-17A Could Predict Acute Disease Severity in Non-NMDA-Receptor Autoimmune Encephalitis. <i>Frontiers in Immunology</i> , 2021, 12, 673021.	4.8	14
211	How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. <i>Journal of Neurology</i> , 2022, 269, 1701-1714.	3.6	14
212	Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo—Associated Paraneoplastic Cerebellar Degeneration. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	14
213	Paraneoplastic opsomyoclonus, cerebellar ataxia and encephalopathy associated with anti-Purkinje cell antibodies. <i>Journal of Neurology</i> , 1997, 244, 333-335.	3.6	13
214	Facial pain as first manifestation of anti-Hu paraneoplastic syndrome. <i>Journal of Headache and Pain</i> , 2010, 11, 355-357.	6.0	13
215	Effect of thymectomy on refractory autoimmune status epilepticus. <i>Journal of Neuroimmunology</i> , 2018, 317, 90-94.	2.3	13
216	Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	13

#	ARTICLE	IF	CITATIONS
217	Recurrent cerebral venous thrombosis revealing paraneoplastic angiitis in Hodgkin's lymphoma. <i>Journal of Neuro-Oncology</i> , 2008, 89, 195-198.	2.9	12
218	Autoimmune limbic encephalitis: an expanding concept. <i>Lancet Neurology</i> , The, 2010, 9, 24-25.	10.2	12
219	PET follow-up in a case of anti-NMDAR encephalitis: arguments for cingulate limbic encephalitis. <i>Epileptic Disorders</i> , 2012, 14, 90-93.	1.3	12
220	Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status. <i>Journal of Neuro-Oncology</i> , 2015, 122, 529-537.	2.9	12
221	Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation. <i>Experimental Cell Research</i> , 2013, 319, 588-599.	2.6	11
222	Neuronal networks in mental diseases and neuropathic pain: Beyond brain derived neurotrophic factor and collapsin response mediator proteins. <i>World Journal of Psychiatry</i> , 2016, 6, 18.	2.7	10
223	M1-Activated Macrophages Migration, A Marker of Aortic Atheroma Progression. <i>Investigative Radiology</i> , 2010, 45, 262-269.	6.2	9
224	Syk kinase is phosphorylated in specific areas of the developing nervous system. <i>Neuroscience Research</i> , 2011, 70, 172-182.	1.9	9
225	Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation. <i>Computational and Mathematical Methods in Medicine</i> , 2015, 2015, 1-7.	1.3	9
226	Molecular Pathogenicity of Anti-NMDA Receptor Autoantibody From Patients With First-Episode Psychosis. <i>American Journal of Psychiatry</i> , 2018, 175, 382-383.	7.2	9
227	Value of Onconeural Antibodies in Checkpoint Inhibitor-Related Toxicities. <i>Annals of Neurology</i> , 2020, 88, 199-200.	5.3	9
228	Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies. <i>Cerebellum</i> , 2020, 19, 715-721.	2.5	9
229	Unclear association between COVID-19 and Guillain-Barré syndrome. <i>Brain</i> , 2021, 144, e45-e45.	7.6	9
230	Gyriform infiltration as imaging biomarker for molecular glioblastomas. <i>Journal of Neuro-Oncology</i> , 2022, 157, 511-521.	2.9	9
231	Ipsilateral ptosis as main feature of tuberothalamic artery infarction. <i>Neurological Sciences</i> , 2009, 30, 69-70.	1.9	8
232	An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	8
233	Therapeutic approaches in antibody-associated central nervous system pathologies. <i>Revue Neurologique</i> , 2014, 170, 587-594.	1.5	8
234	The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study. <i>Journal of Neural Transmission</i> , 2015, 122, 975-991.	2.8	8

#	ARTICLE	IF	CITATIONS
235	Syk kinases are required for spinal commissural axon repulsion at the midline via ephrin/Eph pathway. <i>Development (Cambridge)</i> , 2016, 143, 2183-93.	2.5	8
236	Psychiatric symptoms in anti glutamic acid decarboxylase associated limbic encephalitis in adults: a systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 119, 128-137.	6.1	8
237	LTDpathies: a Novel Clinical Concept. <i>Cerebellum</i> , 2021, , 1.	2.5	8
238	Long-term evolution and prognostic factors of epilepsy in limbic encephalitis with LGI1 antibodies. <i>Journal of Neurology</i> , 0, , .	3.6	8
239	Altered expression of CRMPs in the brain of bovine spongiform encephalopathy-infected mice during disease progression. <i>Brain Research</i> , 2009, 1261, 1-6.	2.2	7
240	Pure monomelic sensory neuropathy associated with antiâ€œyo antibodies. <i>Muscle and Nerve</i> , 2012, 45, 297-298.	2.2	7
241	New Findings in Adult Opsoclonus-Myoclonus Syndrome. <i>JAMA Neurology</i> , 2016, 73, 381.	9.0	7
242	Reversible myoclonusâ€œataxia encephalitis related to antiâ€œmGLUR1 autoantibodies. <i>Movement Disorders</i> , 2019, 34, 438-439.	3.9	7
243	Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy. <i>Journal of NeuroImmune Pharmacology</i> , 2022, 17, 377-379.	4.1	7
244	Opposing Morphogenetic Defects on Dendrites and Mossy Fibers of Dentate Granular Neurons in CRMP3-Deficient Mice. <i>Brain Sciences</i> , 2018, 8, 196.	2.3	6
245	Cerebellar long-term depression and auto-immune target of auto-antibodies: the concept of LTDpathies. <i>Molecular Biomedicine</i> , 2021, 2, 2.	4.4	6
246	Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 652544.	3.7	6
247	Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome. <i>Clinical and Experimental Immunology</i> , 2014, 178, 127-129.	2.6	5
248	Intracranial nonâ€œmyxoid angiomatoid fibrous histiocytoma with <i>EWSR1â€œCREB1</i> transcript fusion treated with doxorubicin: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 131.	1.0	5
249	Is autoimmune limbic encephalitis a channelopathy?. <i>Lancet Neurology</i> , The, 2010, 9, 753-755.	10.2	4
250	Acute Headache Followed by Focal Neuropsychological Impairment in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2010, 19, 75-76.	1.6	4
251	Acuteâ€œonset chorea, dystonia, and cardiac fibroelastoma in a child: A paraneoplastic association?. <i>Movement Disorders</i> , 2013, 28, 250-251.	3.9	4
252	Cerebellar vermis hypermetabolism in opsoclonus myoclonus without onconeural antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e168.	6.0	4

#	ARTICLE	IF	CITATIONS
253	Alterations of cerebral microcirculation in peritumoral edema: feasibility of in vivo sidestream dark-field imaging in intracranial meningiomas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa108.	0.7	4
254	Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. <i>Journal of Neurology</i> , 2021, 268, 2515-2522.	3.6	4
255	GAD65-Ab encephalitis and subtle focal status epilepticus. <i>Epileptic Disorders</i> , 2019, 21, 437-442.	1.3	4
256	Paraneoplastic encephalitis: clinically based approach on diagnosis and management. <i>Postgraduate Medical Journal</i> , 2023, 99, 669-678.	1.8	4
257	A mouse model of autoimmune encephalitis. <i>Brain</i> , 2015, 138, 5-8.	7.6	3
258	Successful Management of Anti-GluR1 Encephalitis with Immunosuppressive Treatment: Dengue Virus as a Trigger?. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 727-728.	1.5	3
259	Structural mapping of hot spots within human CASPR2 discoidin domain for autoantibody recognition. <i>Journal of Autoimmunity</i> , 2019, 96, 168-177.	6.5	3
260	Paraneoplastic Neurological Syndromes. <i>Contemporary Clinical Neuroscience</i> , 2019, , 439-485.	0.3	3
261	Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfilER trial. <i>Medical Oncology</i> , 2022, 39, 4.	2.5	3
262	Magnetic Resonance Imaging: Significance of Early Ischemic Changes on Computed Tomography. <i>Cerebrovascular Diseases</i> , 2004, 18, 232-235.	1.7	2
263	Simultaneous Subarachnoid Hemorrhage and Cerebellar Infarct Revealing Vertebral Artery Aneurysm. <i>Archives of Neurology</i> , 2005, 62, 1158.	4.5	2
264	Les syndromes paranéoplasiques neurologiques. <i>Oncologie</i> , 2009, 11, 83-89.	0.7	2
265	Autoimmune limbic encephalitis. <i>Future Neurology</i> , 2011, 6, 97-111.	0.5	2
266	Autoimmune encephalopathies. <i>Neurology</i> , 2013, 81, 1482-1483.	1.1	2
267	Cyclophosphamide-responsive Lgi1-related limbic encephalitis with basal ganglia hypermetabolism. <i>Acta Neurologica Belgica</i> , 2016, 116, 379-381.	1.1	2
268	Fatal Anti-Ma2 Encephalitis Related to Treatment of Malignant Pleural Mesothelioma With a Combination of Anti-Programmed Death 1 and Anti-Cytotoxic T-Lymphocyte Associated Protein 4 Antibodies. <i>Journal of Thoracic Oncology</i> , 2019, 14, e174-e176.	1.1	2
269	Recurrent seizures of autoimmune origin: emerging phenotypes. <i>Journal of Neurology</i> , 2021, 268, 3000-3010.	3.6	2
270	Abdominal Segmental Myoclonus Mimicking Belly Dancer Dyskinesias in CASPR2 Antibody Encephalomyelitis. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1260-1262.	1.5	2

#	ARTICLE	IF	CITATIONS
271	The Clinical Concept of LTDpathy: Is Dysregulated LTD Responsible for Prodromal Cerebellar Symptoms?. Brain Sciences, 2022, 12, 303.	2.3	2
272	Les syndromes neurologiques paranœoplasiques. Revue De Medecine Interne, 2006, 27, S269-S271.	1.0	1
273	Abnormal expression of truncated CRMP-1 protein in the brain cortex of MPSIIIB mice. Molecular Genetics and Metabolism, 2008, 94, 135-138.	1.1	1
274	From anti-GAD to ataxia with ocular motor apraxia type 2: through the looking glass. Journal of Neurology, 2013, 260, 1158-1159.	3.6	1
275	Forecasting outcomes in anti-NMDAR encephalitis. Neurology, 2019, 92, 119-120.	1.1	1
276	Computer-aided Therapeutics in Treating Autoimmune Encephalitisâ€”Reply. JAMA Neurology, 2016, 73, 128.	9.0	0
277	Neurologiques. , 2010, , 257-262.		0
278	Impact of bevacizumab added to temozolomide-chemoradiation on time to health-related quality of life deterioration in unresectable glioblastoma: Results of a phase II randomized clinical trial.. Journal of Clinical Oncology, 2015, 33, 2018-2018.	1.6	0